Home / Advanced Search

  • Title/Keywords

  • Author/Affliations

  • Journal

  • Article Type

  • Start Year

  • End Year

Update SearchingClear
  • Articles
  • Online
Search Results (39)
  • Open Access


    The Potential Efficacy of Glycyrrhizic Acid and Its Nanostructure Against Brown Rot of Peach fruits

    Tahsin Shoala1, Basma H. Amin2, Ismail A. S. Rashid3, Fayz A. Abdel-Rahman3, Mohamed E. Khalil3, Khamis Youssef3,*

    Phyton-International Journal of Experimental Botany, Vol.92, No.4, pp. 1139-1152, 2023, DOI:10.32604/phyton.2023.026515

    Abstract Production of peaches (Prunus persica (L.) Batsch) for both local market and export is increasing each year in Egypt. Brown rot disease, caused by Monilinia laxa and Monilinia fructigena, is considered one of the most important postharvest rots affecting peaches in Egypt and economic losses are increasing. Antifungal activity of glycyrrhizic acid nanoparticles (GA-NPs) and glycyrrhizic acid (GA) at 0.2 and 0.4 mmol/L was investigated as a control for both these brown rot pathogens on peach fruits in both in vitro and in vivo studies. In the in vitro studies, GA-NPs were the most effective as shown by the ability… More >

  • Open Access


    Glucocorticoid reduces the efficacy of afatinib on the head and neck squamous cell carcinoma


    BIOCELL, Vol.47, No.2, pp. 329-338, 2023, DOI:10.32604/biocell.2023.023489

    Abstract Glucocorticoids (GC) are widely used to counter the adverse events during cancer therapy; nonetheless, previous studies pointed out that GC may reduce the efficacy of chemotherapy on cancer cells, especially in epidermal growth factor receptor (EGFR)-targeted therapy of head and neck squamous cell carcinoma (HNSCC) remaining to be elucidated. The primary aim of the present study was to probe into the GC-induced resistance of EGFR-targeted drug afatinib and the underlying mechanism. HNSCC cell lines (HSC-3, SCC-25, SCC-9, and H-400) and the human oral keratinocyte (HOK) cell lines were assessed for GC receptor (GR) expression. The promoting tumor growth effect of… More >

  • Open Access


    The Efficacy of Deep Learning-Based Mixed Model for Speech Emotion Recognition

    Mohammad Amaz Uddin1, Mohammad Salah Uddin Chowdury1, Mayeen Uddin Khandaker2,*, Nissren Tamam3, Abdelmoneim Sulieman4

    CMC-Computers, Materials & Continua, Vol.74, No.1, pp. 1709-1722, 2023, DOI:10.32604/cmc.2023.031177

    Abstract Human speech indirectly represents the mental state or emotion of others. The use of Artificial Intelligence (AI)-based techniques may bring revolution in this modern era by recognizing emotion from speech. In this study, we introduced a robust method for emotion recognition from human speech using a well-performed preprocessing technique together with the deep learning-based mixed model consisting of Long Short-Term Memory (LSTM) and Convolutional Neural Network (CNN). About 2800 audio files were extracted from the Toronto emotional speech set (TESS) database for this study. A high pass and Savitzky Golay Filter have been used to obtain noise-free as well as… More >

  • Open Access


    Efficacy of Singing Bowls in Childhood Asthma—A Pilot and Feasibility Study

    Sukhbir Shahid*

    Sound & Vibration, Vol.56, No.3, pp. 245-253, 2022, DOI:10.32604/sv.2022.016139

    Abstract The potential use of sound and vibration for diagnostic and therapeutic purposes remains largely under-explored and under-estimated. Sound and vibrational energy has great positive impact on the mind and body. It could be particularly useful for psychosomatic diseases as a complementary therapy. Singing bowls, the spiritual ancient therapy has been claimed to aid in mind relaxation and painful and inflammatory conditions. Childhood asthma is an inflammatory airway disease and a psychosomatic disorder. The psychological management in it is often neglected leading to under-treatment or a relapse. Hence, we hypothesized that sound therapy with singing bowls might be useful as complementary… More >

  • Open Access


    Anticancer efficacy of 3-(4-isopropyl) benzylidene-8-ethoxy, 6-methyl, chroman-4-one (SBL-060), a novel, dual, estrogen receptor-Akt kinase inhibitor in acute myeloid leukemia cells


    Oncology Research, Vol.29, No.3, pp. 149-157, 2021, DOI:10.32604/or.2022.03539

    Abstract Estrogen receptor (ER) α is expressed in a subset of patient-derived acute myeloid leukemia (AML) cells, whereas Akt is predominantly expressed in most types of AML. Targeting AML with dual inhibitors is a novel approach to combat the disease. Herein, we examined a novel small molecule, 3-(4-isopropyl) benzylidene-8-ethoxy,6- methyl, chroman-4-one (SBL-060), capable of targeting AML cells by inhibiting ERα and Akt kinase. The chemical properties of SBL-060 were identified by proton nuclear magnetic resonance (1 H-NMR), 13C-NMR, and mass spectroscopy. In silico docking was performed using an automated protocol with AutoDock-VINA. THP-1 and HL-60 cell lines were differentiated using phorbol… More >

  • Open Access


    Efficacy, Safety and Characteristics of the Amplatzer Vascular Plug II and IV Utilization for Various Percutaneous Occlusions in Children under 10 Years

    Hugues Lucron1,*, Alban-Elouen Baruteau2,3, Caroline Ovaert4, Ali Houeijeh5, Mélanie Brard1, Patrice Guerin2, François Bourlon6, Claire Dauphin7, Saskia Tuttle1, Maha Tagorti3, Rishika Banydeen8, François Godart5

    Congenital Heart Disease, Vol.17, No.4, pp. 421-436, 2022, DOI:10.32604/chd.2022.020835

    Abstract Objectives: We aim to describe the efficacy, safety, and characteristics of the Amplatzer Vascular Plug (AVP) II and IV “off-label” use for multiple cardiovascular occlusions in children under 10 years. Methods: Observational retrospective multicenter (2007–2020, 6 centers) review of paediatric procedures using AVP II or IV. Results: A total of 125 children (49.6% aged ≤ 1 year, 147 lesions) underwent 136 successive procedures (success rate: 98.5%) using 169 devices (109 AVP IV, 60 AVP II). The mean device diameter was 7.7 ± 3.2 mm (4–20 mm). The median AVP size to vessel diameter ratio was 1.3 (0–2). The median age and weight… More > Graphic Abstract

    Efficacy, Safety and Characteristics of the Amplatzer Vascular Plug II and IV Utilization for Various Percutaneous Occlusions in Children under 10 Years

  • Open Access


    Different Types of ROS1 Fusion Partners Yield Comparable Efficacy to Crizotinib

    Yueming He*1, Wang Sheng†1, Weiguo Hu‡1, Jing Lin§, Junjun Liu§, Bing Yu§, Xinru Mao§, Lu Zhang§, Jin Huang, Guangsuo Wang#

    Oncology Research, Vol.27, No.8, pp. 901-910, 2019, DOI:10.3727/096504019X15509372008132

    Abstract ROS1 rearrangements define a distinct molecular subset of non-small-cell lung cancer (NSCLC), which can be treated effectively with crizotinib, a tyrosine kinase inhibitor (TKI) targeting ROS1/MET/ALK rearrangements. Diverse efficacy was observed in ROS1-rearranged NSCLC patients. Because of its rareness, very limited studies have investigated the correlation between different fusion partners and response to crizotinib. In this study, we retrospectively screened 6,235 advanced NSCLC patients (stage IIIB to IV) from five hospitals and identified 106 patients with ROS1 rearrangements based on either plasma or tumor tissue testing using capturebased targeted sequencing. The most frequently occurring fusion partners included cluster of differentiation… More >

  • Open Access


    Synergistic Efficacy of the Demethylation Agent Decitabine in Combination With the Protease Inhibitor Bortezomib for Treating Multiple Myeloma Through the Wnt/b-Catenin Pathway

    Yulong Jin*, Li Xu*, Xiaodong Wu, Juan Feng*, Mimi Shu*, Hongtao Gu*, Guangxun Gao*, Jinyi Zhang, Baoxia Dong*, Xiequn Chen*

    Oncology Research, Vol.27, No.6, pp. 729-737, 2019, DOI:10.3727/096504018X15443011011637

    Abstract Multiple myeloma (MM) is a hematopoietic malignancy characterized by the clonal proliferation of antibodysecreting plasma cells. Bortezomib (BZM), the first FDA-approved proteasome inhibitor, has significant antimyeloma activity and prolongs the median survival of MM patients. However, MM remains incurable predominantly due to acquired drug resistance and disease relapse. -Catenin, a key effector protein in the canonical Wnt signaling pathway, has been implicated in regulating myeloma cell sensitivity to BZM. Decitabine (DAC) is an epigenetic modulating agent that induces tumor suppressor gene reexpression based on its gene-specific DNA hypomethylation. DAC has been implicated in modulating Wnt/ -catenin signaling by promoting the… More >

  • Open Access


    Efficacy and Safety of CalliSpheres® Drug-Eluting Beads Transarterial Chemoembolization in Barcelona Clinic Liver Cancer Stage C Patients

    Yaohong Liu, Wensou Huang, Mingji He, Hui Lian, Yongjian Guo, Jingjun Huang, Jingwen Zhou, Kangshun Zhu

    Oncology Research, Vol.27, No.5, pp. 565-573, 2019, DOI:10.3727/096504018X15313896322888

    Abstract This study aimed to investigate the efficacy and safety of drug-eluting beads transarterial chemoembolization (DEB-TACE) treatment in Barcelona Clinic Liver Cancer (BCLC) stage C liver cancer patients. In 39 patients with BCLC stage C liver cancer, after the first cycle of DEB-TACE, 2 (5.1%) and 24 (61.5%) patients achieved complete response (CR) and partial response (PR) to give an overall objective response rate (ORR) of 66.7%. With respect to the second cycle of therapy, the ORR was higher in patients receiving DEB-TACE compared with those receiving cTACE (57.1% vs. 11.1%). After the first cycle of DEB-TACE treatment, the percentages of… More >

  • Open Access


    Efficacy Evaluation of Imatinib for the Treatment of Melanoma: Evidence From a Retrospective Study

    Xiaoting Wei, Lili Mao, Zhihong Chi, Xinan Sheng, Chuanliang Cui, Yan Kong, Jie Dai, Xuan Wang, Siming Li, Bixia Tang, Bin Lian, Xieqiao Yan, Xue Bai, Li Zhou, Jun Guo, Lu Si

    Oncology Research, Vol.27, No.4, pp. 495-501, 2019, DOI:10.3727/096504018X15331163433914

    Abstract Melanoma is an aggressive malignancy with a poor prognosis. Current studies show that imatinib treatment is a promising approach in treating advanced melanoma patients harboring c-Kit mutations or amplifications. We retrospectively analyzed the clinical medical records of 78 patients with metastatic melanoma harboring c-Kit mutations or amplifications. These patients were treated with imatinib at a dose of 400 mg/day continuously unless intolerable toxicities or disease progression occurred. Endpoints for exploration included overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and disease of control rate (DCR). The median OS and PFS of all patients were 13.1 and 4.2 months,… More >

Displaying 1-10 on page 1 of 39. Per Page  

Share Link